[go: up one dir, main page]

BRPI1012666B8 - cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso - Google Patents

cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso

Info

Publication number
BRPI1012666B8
BRPI1012666B8 BRPI1012666A BRPI1012666A BRPI1012666B8 BR PI1012666 B8 BRPI1012666 B8 BR PI1012666B8 BR PI1012666 A BRPI1012666 A BR PI1012666A BR PI1012666 A BRPI1012666 A BR PI1012666A BR PI1012666 B8 BRPI1012666 B8 BR PI1012666B8
Authority
BR
Brazil
Prior art keywords
etravirine
cocrystal
nicotinamide
preparation
combination
Prior art date
Application number
BRPI1012666A
Other languages
English (en)
Inventor
F Remenar Julius
Elvire Colette Baert Lieven
Tawa Mark
F Sansone Matthew
Original Assignee
Janssen R&D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R&D Ireland
Publication of BRPI1012666A2 publication Critical patent/BRPI1012666A2/pt
Publication of BRPI1012666B1 publication Critical patent/BRPI1012666B1/pt
Publication of BRPI1012666B8 publication Critical patent/BRPI1012666B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso. a presente invenção refere-se a um cocristal de etravirina (tmc125) nicotinamida, sua preparação, e uso no tratamento de infecção por hiv.
BRPI1012666A 2009-03-30 2010-03-26 cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso BRPI1012666B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16451609P 2009-03-30 2009-03-30
US61/164,516 2009-03-30
PCT/EP2010/053970 WO2010112411A1 (en) 2009-03-30 2010-03-26 Co-crystal of etravirine and nicotinamide

Publications (3)

Publication Number Publication Date
BRPI1012666A2 BRPI1012666A2 (pt) 2016-04-05
BRPI1012666B1 BRPI1012666B1 (pt) 2020-12-22
BRPI1012666B8 true BRPI1012666B8 (pt) 2021-05-25

Family

ID=42340730

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012666A BRPI1012666B8 (pt) 2009-03-30 2010-03-26 cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso

Country Status (10)

Country Link
US (1) US8754093B2 (pt)
EP (1) EP2413936B1 (pt)
JP (1) JP5748737B2 (pt)
CN (1) CN102369009B (pt)
AU (1) AU2010230344B9 (pt)
BR (1) BRPI1012666B8 (pt)
CA (1) CA2757228C (pt)
EA (1) EA024299B1 (pt)
ES (1) ES2612485T3 (pt)
WO (1) WO2010112411A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102859351B (zh) * 2010-04-27 2015-05-27 丰田自动车株式会社 涡流计测用传感器
KR101336143B1 (ko) 2011-09-26 2013-12-05 한밭대학교 산학협력단 클로피도그렐의 공결정
CA2876539A1 (en) * 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
CN103864606A (zh) * 2012-12-17 2014-06-18 中国科学院苏州纳米技术与纳米仿生研究所 二氟尼柳和吡啶甲酰胺类化合物的共晶体及其制备方法
EP3148982A1 (en) 2014-05-27 2017-04-05 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US10508096B2 (en) 2014-05-27 2019-12-17 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US9896429B2 (en) 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
EP3266445B1 (en) * 2015-03-02 2022-05-11 Takeda Pharmaceutical Company Limited Suspension or composition containing nano-cocrystal and manufacturing method therefor
CN108495563B (zh) 2015-11-25 2022-04-26 R.J.雷诺兹烟草公司 烟碱盐、共晶体和盐共晶体配合物
WO2019049049A1 (en) 2017-09-05 2019-03-14 R. J. Reynolds Tobacco Company SALTS, CO-CRYSTALS, AND CO-CRYSTAL COMPLEXES OF NICOTINE SALTS
CN113024362B (zh) * 2021-03-10 2022-02-15 中国科学院上海药物研究所 一种辅酶qh与烟酰胺的共晶及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
US20070135488A1 (en) * 2002-04-13 2007-06-14 Chung You S Amlodipine nicotinate and process for the preparation thereof
US20100041687A1 (en) * 2006-12-06 2010-02-18 Thone Daniel Joseph Christiaan Hydrobromide salt of an anti-hiv compound
US20110244496A1 (en) * 2007-03-06 2011-10-06 Rutgers, The State University Hiv reverse transcriptase compositions and methods
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz

Also Published As

Publication number Publication date
BRPI1012666A2 (pt) 2016-04-05
EP2413936A1 (en) 2012-02-08
CN102369009A (zh) 2012-03-07
HK1167829A1 (en) 2012-12-14
JP2012522026A (ja) 2012-09-20
US20120028998A1 (en) 2012-02-02
EP2413936B1 (en) 2016-11-02
BRPI1012666B1 (pt) 2020-12-22
JP5748737B2 (ja) 2015-07-15
WO2010112411A1 (en) 2010-10-07
CA2757228C (en) 2018-01-02
ES2612485T3 (es) 2017-05-17
AU2010230344B9 (en) 2014-11-27
CN102369009B (zh) 2014-04-30
AU2010230344B2 (en) 2014-07-24
EA024299B1 (ru) 2016-09-30
US8754093B2 (en) 2014-06-17
CA2757228A1 (en) 2010-10-07
EA201171186A1 (ru) 2012-05-30
AU2010230344A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
CL2007001847A1 (es) Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
MD4841B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
BR112014022214A2 (pt) fenólicos antibacterianos
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
WO2008118849A3 (en) Hiv-1 protease inhibitors
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/513 (2006.01), A61K 9/48 (2006.0

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF